Literature DB >> 3827277

Cholinergic urticaria. A clinical and histologic study.

J V Hirschmann, F Lawlor, J S English, J B Louback, R K Winkelmann, M W Greaves.   

Abstract

We studied the natural history, the prevalence of atopy, and the frequency of systemic symptoms during attacks in 35 patients with cholinergic urticaria, the histologic condition of the eruption in seven patients (20%), and the response to intradermal injections of acetylcholine, histamine, and methacholine in 18 patients (51%). In most patients symptoms began between the ages of 10 and 30 years, persisted for many years, and caused them to modify their activities to avoid the provoking factors of exercise, emotion, and heat. The condition usually improved with time, and five patients (14%) had a spontaneous remission. Atopy, present in about 12 (34%) of the patients, was more frequent than in the general population. Systemic symptoms were uncommon during attacks, and patients had no greater responses than controls to the intradermal tests. The histologic study revealed neutrophils in and around the walls of superficial subpapillary dermal vessels.

Entities:  

Mesh:

Year:  1987        PMID: 3827277     DOI: 10.1001/archderm.123.4.462

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  10 in total

Review 1.  Exercise-induced anaphylaxis (EIA).

Authors:  M C Castells; R F Horan; A L Sheffer
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management.

Authors:  Atsushi Fukunaga; Ken Washio; Mayumi Hatakeyama; Yoshiko Oda; Kanako Ogura; Tatsuya Horikawa; Chikako Nishigori
Journal:  Clin Auton Res       Date:  2017-04-05       Impact factor: 4.435

Review 3.  Evaluating chronic urticaria patients for allergies, infections, or autoimmune disorders.

Authors:  Y C Wai; Gordon L Sussman
Journal:  Clin Rev Allergy Immunol       Date:  2002-10       Impact factor: 8.667

Review 4.  New concepts of hive formation in cholinergic urticaria.

Authors:  Tastuya Horikawa; Atsushi Fukunaga; Chikako Nishigori
Journal:  Curr Allergy Asthma Rep       Date:  2009-07       Impact factor: 4.806

5.  Quantitative Characterization of the Neuropeptide Level Changes in Dorsal Horn and Dorsal Root Ganglia Regions of the Murine Itch Models.

Authors:  Emily G Tillmaand; Krishna D B Anapindi; Eduardo A De La Toba; Changxiong J Guo; Jessica Krebs; Ashley E Lenhart; Qin Liu; Jonathan V Sweedler
Journal:  J Proteome Res       Date:  2020-02-03       Impact factor: 4.466

6.  Cholinergic Urticaria: Clinical Presentation and Natural History in a Tropical Country.

Authors:  Chuda Rujitharanawong; Papapit Tuchinda; Leena Chularojanamontri; Nattacha Chanchaemsri; Kanokvalai Kulthanan
Journal:  Biomed Res Int       Date:  2020-05-24       Impact factor: 3.411

7.  Cholinergic Urticaria, an Effective and Safe "Off Label" Use of Dupilumab: A Case Report with Literature Review.

Authors:  Maria Maddalena Sirufo; Alessandra Catalogna; Martina Raggiunti; Francesca De Pietro; Lia Ginaldi; Massimo De Martinis
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-02-18

8.  Impaired sweating in patients with cholinergic urticaria is linked to low expression of acetylcholine receptor CHRM3 and acetylcholine esterase in sweat glands.

Authors:  Yiyu Wang; Jörg Scheffel; Carolina Ayala Vera; Wei Liu; Dorothee Günzel; Dorothea Terhorst-Molawi; Marcus Maurer; Sabine Altrichter
Journal:  Front Immunol       Date:  2022-07-29       Impact factor: 8.786

Review 9.  Cholinergic Urticaria: Subtype Classification and Clinical Approach.

Authors:  Atsushi Fukunaga; Yoshiko Oda; Shinya Imamura; Mayuko Mizuno; Takeshi Fukumoto; Ken Washio
Journal:  Am J Clin Dermatol       Date:  2022-09-15       Impact factor: 6.233

10.  Sensitization against skin resident fungi is associated with atopy in cholinergic urticaria patients.

Authors:  Sabine Altrichter; Pia Schumacher; Ola Alraboni; Yiyu Wang; Makiko Hiragun; Michihiro Hide; Marcus Maurer
Journal:  Clin Transl Allergy       Date:  2020-06-01       Impact factor: 5.871

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.